Creep Strength and Microstructure of AL20-25+Nb Alloy Sheets and Foils for Advanced Microturbine Recuperators

2006 ◽  
Vol 129 (3) ◽  
pp. 798-805 ◽  
Author(s):  
P. J. Maziasz ◽  
J. P. Shingledecker ◽  
N. D. Evans ◽  
Y. Yamamoto ◽  
K. L. More ◽  
...  
Keyword(s):  
Creep Resistance ◽  
Phase 1 ◽  
National Laboratory ◽  
Rupture Life ◽  
Test Facility ◽  
Phase 2 ◽  
Oak Ridge ◽  
Collaborative Program ◽  
Wide Range ◽  
Air Cells

The Oak Ridge National Laboratory (ORNL) and ATI Allegheny Ludlum worked together on a collaborative program for about two years to produce a wide range of commercial sheets and foils of the new AL20-25+Nb™ (AL20–25+Nb) stainless alloy for advanced microturbine recuperator applications. There is a need for cost-effective sheets/foils with more performance and reliability at 650–750°C than 347 stainless steel, particularly for larger 200–250 kW microturbines. Phase 1 of this collaborative program produced the sheets and foils needed for manufacturing brazed plated-fin air cells, while Phase 2 provided foils for primary surface air cells, and did experiments on modified processing designed to change the microstructure of sheets and foils for improved creep-resistance. Phase 1 sheets and foils of AL20-25+Nb have much more creep-resistance than 347 steel at 700–750°C, and those foils are slightly stronger than HR120 and HR230. Results for Phase 2 showed nearly double the creep-rupture life of sheets at 750°C/100 MPa, and similar improvements in foils. Creep data show that Phase 2 foils of AL20-25+Nb alloy have creep resistance approaching that of alloy 625 foils. Testing at about 750°C in flowing turbine exhaust gas for 500 h in the ORNL Recuperator Test Facility shows that foils of AL20–25+Nb alloy have oxidation-resistance similar to HR120 alloy, and much better than 347 steel.

Creep Strength and Microstructure of AL20-25+Nb Alloy Sheets and Foils for Advanced Microturbine Recuperators

2006 ◽  
Author(s):  
Philip J. Maziasz ◽  
John P. Shingledecker ◽  
Neal D. Evans ◽  
Yukinori Yamamoto ◽  
Karren L. More ◽  
...  
Keyword(s):  
Phase I ◽  
Phase Ii ◽  
Creep Resistance ◽  
National Laboratory ◽  
Rupture Life ◽  
Cost Effective ◽  
Test Facility ◽  
Oak Ridge ◽  
Collaborative Program ◽  
Wide Range

The Oak Ridge National Laboratory (ORNL) and ATI Allegheny-Ludlum began a collaborative program in 2004 to produce a wide range of commercial sheets and foils of the new AL20-25+Nb stainless alloy, specifically designed for advanced microturbine recuperator applications. There is a need for cost-effective sheets/foils with more performance and reliability at 650–750°C than 347 stainless steel, particularly for larger 200–250 kW microturbines. Phase I of this collaborative program produced the sheets and foils needed for manufacturing brazed plated-fin (BPF) aircells, while Phase II provided foils for primary surface (PS) aircells, and modified processing to change the microstructure of sheets and foils for improved creep-resistance. Phase I sheets and foils of AL20-25+Nb have much more creep-resistance than 347 steel at 700–750°C, and foils are slightly stronger than HR120 and HR230. Preliminary results for Phase II show nearly double the creep-rupture life of sheets at 750°C/100 MPa, with the first foils tested approaching the creep resistance of alloy 625 foils. AL20-25+Nb alloy foils are also now being tested in the ORNL Recuperator Test Facility.

Developing New Cast Austenitic Stainless Steels With Improved High-Temperature Creep Resistance

2007 ◽  
Author(s):  
Philip J. Maziasz ◽  
John P. Shingledecker ◽  
Neal D. Evans ◽  
Michael J. Pollard
Keyword(s):  
Stainless Steel ◽  
High Temperature ◽  
Creep Strength ◽  
Stainless Steels ◽  
Creep Resistance ◽  
National Laboratory ◽  
Austenitic Stainless Steels ◽  
Alloy Development ◽  
Oak Ridge ◽  
Wide Range

Oak Ridge National Laboratory (ORNL) and Caterpillar have recently developed a new cast austenitic stainless steel, CF8C-Plus, for a wide range of high-temperature applications, including diesel exhaust components and turbine casings. The creep-rupture life of the new CF8C-Plus is over ten times greater than that of the standard cast CF8C stainless steel, and the creep-strength is about double. Another variant, CF8C-Plus Cu/W has been developed with even more creep strength at 750–850°C. The creep-strength of these new cast austenitic stainless steels is close to that of Ni-based superalloys like 617. CF8C-Plus steel was developed in about 1.5 years using an “engineered microstructure” alloy development approach, which produces creep resistance based on formation of stable nano-carbides (NbC) and prevention of deleterious intermetallics (sigma, Laves). CF8C-Plus steel won a 2003 R&D 100 Award, and to date, over 32,000 lb have been produced in various commercial component trials. The current commercialization status of the alloy is summarized.

scholarly journals Octane Index Applicability over the Pressure-Temperature Domain

Energies ◽  
2021 ◽  
Vol 14 (3) ◽  
pp. 607
Author(s):  
Tommy R. Powell ◽  
James P. Szybist ◽  
Flavio Dal Forno Chuahy ◽  
Scott J. Curran ◽  
John Mengwasser ◽  
...  
Keyword(s):  
High Efficiency ◽  
National Laboratory ◽  
Operating Conditions ◽  
Dominant Factor ◽  
Compression Ignition ◽  
Oak Ridge ◽  
Operating Modes ◽  
Wide Range ◽  
Thermodynamic Conditions ◽  
Si Engines

Modern boosted spark-ignition (SI) engines and emerging advanced compression ignition (ACI) engines operate under conditions that deviate substantially from the conditions of conventional autoignition metrics, namely the research and motor octane numbers (RON and MON). The octane index (OI) is an emerging autoignition metric based on RON and MON which was developed to better describe fuel knock resistance over a broader range of engine conditions. Prior research at Oak Ridge National Laboratory (ORNL) identified that OI performs reasonably well under stoichiometric boosted conditions, but inconsistencies exist in the ability of OI to predict autoignition behavior under ACI strategies. Instead, the autoignition behavior under ACI operation was found to correlate more closely to fuel composition, suggesting fuel chemistry differences that are insensitive to the conditions of the RON and MON tests may become the dominant factor under these high efficiency operating conditions. This investigation builds on earlier work to study autoignition behavior over six pressure-temperature (PT) trajectories that correspond to a wide range of operating conditions, including boosted SI operation, partial fuel stratification (PFS), and spark-assisted compression ignition (SACI). A total of 12 different fuels were investigated, including the Co-Optima core fuels and five fuels that represent refinery-relevant blending streams. It was found that, for the ACI operating modes investigated here, the low temperature reactions dominate reactivity, similar to boosted SI operating conditions because their PT trajectories lay close to the RON trajectory. Additionally, the OI metric was found to adequately predict autoignition resistance over the PT domain, for the ACI conditions investigated here, and for fuels from different chemical families. This finding is in contrast with the prior study using a different type of ACI operation with different thermodynamic conditions, specifically a significantly higher temperature at the start of compression, illustrating that fuel response depends highly on the ACI strategy being used.

scholarly journals A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

2020 ◽  
Vol 8 (1) ◽  
pp. e000530 ◽  
Author(s):  
Aung Naing ◽  
Justin F Gainor ◽  
Hans Gelderblom ◽  
Patrick M Forde ◽  
Marcus O Butler ◽  
...  
Keyword(s):  
Adverse Events ◽  
Solid Tumors ◽  
Phase 1 ◽  
Clinical Activity ◽  
Advanced Solid Tumors ◽  
Phase 2 ◽  
Dose Escalation Study ◽  
Wide Range ◽  
Tumor Types ◽  
Tumor Biopsies

BackgroundSpartalizumab is a humanized IgG4κ monoclonal antibody that binds programmed death-1 (PD-1) and blocks its interaction with PD-L1 and PD-L2. This phase 1/2 study was designed to assess the safety, pharmacokinetics, and preliminary efficacy of spartalizumab in patients with advanced or metastatic solid tumors.MethodsIn the phase 1 part of the study, 58 patients received spartalizumab, intravenously, at doses of 1, 3, or 10 mg/kg, administered every 2 weeks (Q2W), or 3 or 5 mg/kg every 4 weeks (Q4W).ResultsPatients had a wide range of tumor types, most commonly sarcoma (28%) and metastatic renal cell carcinoma (10%); other tumor types were reported in ≤3 patients each. Most patients (93%) had received prior antineoplastic therapy (median three prior lines) and two-thirds of the population had tumor biopsies negative for PD-L1 expression at baseline. The maximum tolerated dose was not reached. The recommended phase 2 doses were selected as 400 mg Q4W or 300 mg Q3W. No dose-limiting toxicities were observed, and adverse events included those typical of other PD-1 antibodies. The most common treatment-related adverse events of any grade were fatigue (22%), diarrhea (17%), pruritus (14%), hypothyroidism (10%), and nausea (10%). Partial responses occurred in two patients (response rate 3.4%); one with atypical carcinoid tumor of the lung and one with anal cancer. Paired tumor biopsies from patients taken at baseline and on treatment suggested an on-treatment increase in CD8+ lymphocyte infiltration in patients with clinical benefit.ConclusionsSpartalizumab was well tolerated at all doses tested in patients with previously treated advanced solid tumors. On-treatment immune activation was seen in tumor biopsies; however, limited clinical activity was reported in this heavily pretreated, heterogeneous population. The phase 2 part of this study is ongoing in select tumor types.Trial registration numberNCT02404441.

scholarly journals Shared Research Equipment at OAK Ridge National Laboratory

1998 ◽  
Vol 4 (S2) ◽  
pp. 470-471
Author(s):  
N. D. Evans ◽  
E. A. Kenik ◽  
M. K. Miller
Keyword(s):  
Semiconductor Device ◽  
National Laboratory ◽  
Atomic Scale ◽  
Fiscal Year ◽  
Probe Field ◽  
Oak Ridge ◽  
Wide Range ◽  
Oak Ridge National Laboratory ◽  
Electron Microscopes ◽  
Research Equipment

The Shared Research Equipment (SHaRE) User Facility and Program at Oak Ridge National Laboratory (ORNL) provides microanalytical facilities for studies within the materials sciences. Available instrumentation includes advanced analytical electron microscopes, atom probe field ion microscopes, and nanoindentation facilities. Through SHaRE, researchers from U.S. universities, industries, and government laboratories may collaborate with Facility scientists to perform research not possible at their home institutions. International collaborations are also possible. Most SHaRE projects seek correlations at the microscopic or atomic scale between structure and properties in a wide range of metallic, ceramic, and other structural materials. Typical research projects include studies of magnetic materials, advanced alloys, catalysts, semiconductor device materials, high Tc superconductors, and surface-modified polymers. Projects usually involve one or more external researchers visiting the SHaRE Facility for up to three weeks during the fiscal year (October 1 - September 30). Project approval is based upon the scientific excellence and relevance of proposed collaborative research.

scholarly journals P011 Sharing is caring: a regional service development project exploring secondary immunosuppression in children

Rheumatology ◽  
2021 ◽  
Vol 60 (Supplement_1) ◽  
Author(s):  
Joshua L Bennett ◽  
Christo Tsilifis ◽  
Aisling Flinn ◽  
Thomas Altmann ◽  
Nathaniel Jansen ◽  
...  
Keyword(s):  
Information Sharing ◽  
Phase 1 ◽  
Development Project ◽  
Service Development ◽  
Phase 2 ◽  
Phase 3 ◽  
Immunomodulatory Agents ◽  
Immunomodulatory Agent ◽  
Children's Hospital ◽  
Wide Range

Abstract Background/Aims  The range of approved immunosuppressive and immunomodulatory (IM) agents has grown considerably with an increasing list of indications across paediatric specialties. At present, there is limited evidence supporting best practice for prescribing and monitoring of IM agents in children and young people (CYP). We present a staged service development project exploring cross-specialty prescribing and monitoring of IM agents at a tertiary children’s hospital (Great North Children’s Hospital, GNCH) and data sharing with local hospitals across northeast England. Methods  In Phase 1, we searched pharmacy databases and surveyed specialty teams in GNCH to identify clinicians regularly prescribing IM agents to CYP over a twelve-month period. Phase 2 was a cross-specialty retrospective case-notes review of prescribing, monitoring and infection surveillance in a representative sample of CYP on IM agents. Phase 3 explored information sharing with six other hospitals in the region and acute presentations to these sites involving CYP on IM agents. Results  Phase 1 identified 9 paediatric and 2 adult specialties prescribing IM agents to 416 CYP. 32 discrete IM therapies were prescribed with significant between-specialty overlap in drugs prescribed but a wide range of prescribing and monitoring practices. Phase 2 assessed 77 CYP on IM agents in detail - 57% were prescribed >1 IM agent, 100% had FBC measured at least once (range once only to weekly), 18% developed lymphopenia at least once and 40% were prescribed prophylactic antibiotics. Previous varicella exposure had been assessed in 70%. Phase 3 data are summarised in Table 1. P011 Table 1:Information sharing and acute presentations to regional hospitals local to immunosuppressed patientsTotal number of patients141Mean age in years (range)11 (2 - 17)NDiagnosisJIA without uveitis108JIA with uveitis9Uveitis alone8Systemic JIA4Period fever4Behçet’s disease2Juvenile dermatomyositis2Scleroderma1Juvenile systemic lupus erythematosus1Mixed connective tissue disease1Granulomatosis with polyangiitis1Immunosuppressive or immunomodulatory agent usedAdalimumab65Methotrexate42Tocilizumab22Mycophenolate mofetil10Etanercept10Infliximab5Sulfasalazine5Prednisolone4Abatacept4Leflunomide4Canakinumab2Colchicine2Anakinra2Rituximab2Cyclophosphamide1Number of immunosuppressive or immunomodulatory agents per patient3 agents52 agents441 agent92Number of acute presentations by diagnosis or presenting complaint (n = 19)Fever4Chickenpox4Viral upper respiratory tract infection2Joint pain2Abdominal pain2Rash2Eye infection1Tonsilitis1Wheeze1Yes (%)No (%)Named local consultant (n = 129)3763Correct diagnosis recorded locally (n = 130)8020Correct immunosuppressive or immunomodulatory agent recorded locally (n = 130)5050Open access for febrile illness (n = 116)4159Reviewed in past 2 years for acute illness (n = 109)1783Note: presented numbers for immunosuppressive or immunomodulatory agents are not mutually exclusive. JIA, juvenile idiopathic arthritis Conclusion  IM agents are central to modern paediatric clinical care across a wide range of diseases. This staged project identified significant variation in IM prescribing and monitoring practice between specialties at GNCH. Communication between specialty and local teams is inadequate. Particular areas of concern include limited diagnostic, blood monitoring and medication information sharing and limited local information governing management of intercurrent illness and vaccination. Although different disease processes can necessitate different advice and prescribing practices, sharing examples of good practice will minimise unnecessary variation. We propose the development of a regional immunosuppression working group to improve quality and safety across our region. Disclosure  J.L. Bennett: None. C. Tsilifis: None. A. Flinn: None. T. Altmann: None. N. Jansen: None. H. Tumelty: None. K. Aitken: None. S. Bhopal: None. E. Harrison: None. S. Ravenscroft: None. E. Sen: None. E. Williams: None. T. Flood: None. S. Sampath: None. A. Battersby: None. F. McErlane: None.

Production function for short-rotation woody-crop Populus spp. plantations

1994 ◽  
Vol 24 (1) ◽  
pp. 180-184 ◽  
Author(s):  
David A. Lortz ◽  
David R. Betters ◽  
Lynn L. Wright
Keyword(s):  
Production Function ◽  
Cultural Practices ◽  
National Laboratory ◽  
Development Program ◽  
The United States ◽  
Oak Ridge ◽  
Short Rotation ◽  
Wide Range ◽  
Woody Crop ◽  
Populus Spp

Short-rotation woody-crop Populus spp. plantations have the potential to produce large amounts of biomass in short time periods, typically 4–8 years. A production function equation is shown to predict yields for such plantations. The equation is based, in part, on information from biomass production experiments conducted across the United States. These experimental plots are sponsored by the Biofuels Feedstock Development Program of Oak Ridge National Laboratory. The equation uses nine parameters including both cultural practices and climatic and soil site conditions as independent variables. The equation (R2 = 0.86) is accurate and applicable to a wide range of conditions.

scholarly journals Conceptual Design of a MEDE Treatment System for Sodium Bonded Fuel

2008 ◽  
Author(s):  
Carl E. Baily ◽  
Karen A. Moore ◽  
Collin J. Knight ◽  
Peter B. Wells ◽  
Paul J. Petersen ◽  
...  
Keyword(s):  
Spent Nuclear Fuel ◽  
National Laboratory ◽  
Department Of Energy ◽  
Test Facility ◽  
Evaporation Chamber ◽  
Oak Ridge ◽  
Uranium Fuel ◽  
Fuel Assemblies ◽  
Metal Fuel ◽  
Enriched Uranium

Unirradiated sodium bonded metal fuel and casting scrap material containing highly enriched uranium (HEU) is stored at the Materials and Fuels Complex (MFC) on the Idaho National Laboratory (INL). This material, which includes intact fuel assemblies and elements from the Fast Flux Test Facility (FFTF) and Experimental Breeder Reactor-II (EBR-II) reactors, as well as scrap material from the casting of these fuels, has no current use under the terminated reactor programs for both facilities. The Department of Energy (DOE), under the Sodium-Bonded Spent Nuclear Fuel Treatment Record of Decision (ROD), has determined that this material could be prepared and transferred to an off-site facility for processing and eventual fabrication of fuel for commercial nuclear reactors. A plan is being developed to prepare, package, and transfer this material to the DOE HEU Disposition Program Office (HDPO), located at the Y-12 National Security Complex in Oak Ridge, Tennessee. Disposition of the sodium bonded material will require separating the elemental sodium from the metallic uranium fuel. A sodium distillation process known as MEDE (Melt-Drain-Evaporate), will be used for the separation process. The casting scrap material needs to be sorted to remove any foreign material or fines that are not acceptable to the HDPO program. Once all elements have been cut and loaded into baskets, they are then loaded into an evaporation chamber as the first step in the MEDE process. The chamber will be sealed and the pressure reduced to approximately 200 mtorr. The chamber will then be heated as high as 650 °C, causing the sodium to melt and then vaporize. The vapor phase sodium will be driven into an outlet line where it is condensed and drained into a receiver vessel. Once the evaporation operation is complete, the system is de-energized and returned to atmospheric pressure. This paper describes the MEDE process as well as a general overview of the furnace systems, as necessary, to complete the MEDE process.

Sign in / Sign up

Export Citation Format

Share Document